Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A AI Stock Analysis
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A (1762) AI Stock Analysis
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A
(TWSE:1762)
The overall score is very low, driven primarily by a collapse in financial performance, with the company's revenue in freefall and profitability turning deeply negative. This fundamental distress is strongly confirmed by extremely bearish technicals, with the stock in a clear downtrend and showing no signs of momentum. The negative earnings and negligible dividend yield offer no valuation support. The company's trajectory is unsustainable without a major turnaround.
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A (1762) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 2.22B
- Dividend Yield
- 0.64%
- Average Volume (3M)
- 95.33K
- Price to Earnings (P/E)
- -55.8
- Beta (1Y)
- 0.67
- Revenue Growth
- 2.05%
- EPS Growth
- ―
- Country
- TW
- Employees
- 243
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A Business Overview & Revenue Model
Company Description
Based in New Taipei City, Taiwan, Chunghwa Chemical Synthesis & Biotech Co., Ltd., established in 1964 and previously known as China Chemical Synthesis Industry Co., Ltd., specializes in the development, production, and distribution of active pharmac...
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A Financial Statement Overview
Summary
Financial performance is critically weak. The income statement shows a severe revenue decline and negative gross margins, indicating the core business is loss-making. The cash flow score is very low due to volatile and declining cash generation. The balance sheet is the only relative bright spot with low leverage, but the trend of increasing debt and shrinking equity is concerning. The overall financial health is poor.
Income Statement
8Very NegativeBalance Sheet
55NeutralCash Flow
30Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 934.29M | 804.88M | 1.35B | 2.09B | 2.12B | 1.93B |
| Gross Profit | 167.67M | -8.86M | 394.32M | 757.31M | 961.76M | 949.39M |
| EBITDA | 151.05M | -47.60M | 277.66M | 545.93M | 743.72M | 651.27M |
| Net Income | -51.70M | -243.85M | 53.03M | 264.91M | 465.87M | 400.78M |
Balance Sheet | ||||||
| Total Assets | 4.36B | 4.32B | 4.76B | 5.17B | 4.56B | 4.38B |
| Cash, Cash Equivalents and Short-Term Investments | 329.96M | 216.44M | 222.28M | 269.57M | 300.61M | 195.25M |
| Total Debt | 755.63M | 805.86M | 858.17M | 1.21B | 604.54M | 753.55M |
| Total Liabilities | 1.16B | 1.23B | 1.41B | 1.82B | 1.37B | 1.49B |
| Stockholders Equity | 3.20B | 3.09B | 3.36B | 3.35B | 3.19B | 2.89B |
Cash Flow | ||||||
| Free Cash Flow | 248.54M | 80.28M | 362.96M | -517.83M | 357.60M | -186.27M |
| Operating Cash Flow | 290.90M | 142.61M | 467.65M | -66.27M | 733.78M | 219.18M |
| Investing Cash Flow | -60.36M | -61.80M | -100.10M | -461.32M | -376.18M | -802.75M |
| Financing Cash Flow | -116.12M | -86.03M | -415.72M | 496.57M | -253.32M | 630.62M |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A Peers Comparison
Overall Rating
TW:843286Outperform
TW:178071Outperform
TW:840349Neutral
TW:410847Neutral
TW:176238Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 86Outperform | TWD 2.36B | 11.08 | ― | 4.28% | 20.56% | 67.85% | |
| 71Outperform | TWD 2.45B | 20.60 | ― | 5.57% | ― | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | TWD 2.46B | 12.09 | ― | 3.35% | 6.25% | 14.37% | |
| 47Neutral | TWD 2.03B | -75.06 | ― | ― | 1.10% | 56.29% | |
| 38Underperform | TWD 2.32B | -55.83 | ― | 0.64% | 2.05% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:1762 | Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A | 30.15 | 5.80 | 23.82% | |
| TW:1780 | Allied Biotech Corp | 22.45 | 3.45 | 18.15% | |
| TW:4108 | Phytohealth Corporation | 10.20 | -3.70 | -26.62% | |
| TW:7860 | Teh Seng Pharmaceutical Mfg Co Ltd | 77.50 | 9.98 | 14.78% | |
| TW:8403 | ShareHope Medicine Co., Ltd. | 17.90 | -4.93 | -21.58% | |
| TW:8432 | TSH Biopharm Corp. Ltd. | 61.00 | 11.08 | 22.20% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
